Connecting hydroxychloroquine in vitro antiviral activity to in vivo concentration for prediction of antiviral effect: a critical step in treating COVID-19 patients
Translation of in vitro antiviral activity to the in vivo setting is crucial to identify potentially effective dosing regimens of hydroxychloroquine. In vitro EC50/EC90 values for hydroxychloroquine should be compared to the in vivo free extracellular tissue concentration, which is similar to the free plasma hydroxychloroquine concentration.
Explore frequently updated evidence-based guidelines to support patients, clinicians and other health-care professionals in their decisions about treatment and management of patients with COVID-19 infection.
For your free access to this journal, log in via the IDSA members area.
Register to receive email alerts, and keep up to date with the latest Clinical Infectious Diseases articles as soon as they are published online. And, with the IDSA Journals app, it's easy to stay connected, giving you the freedom to read the journal both online and offline, on your iPad, iPhone, or iPod Touch.
Sign up for alerts
- Plague and Bioterrorism Preparedness
- Consensus Position on the Shigella Controlled Human Infection Model
- The Development of Cefiderocol (S-649266), A Novel Siderophore Cephalosporin, in the Era of Multidrug-Resistant Gram-Negative Bacterial Infection
- The Severe Typhoid Fever in Africa (SETA) Program
- Supplement Archive